Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.36
IDXX's Cash to Debt is ranked higher than
52% of the 294 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. IDXX: 0.36 )
IDXX' s 10-Year Cash to Debt Range
Min: 0.36   Max: 240.89
Current: 0.36

0.36
240.89
Equity to Asset 0.09
IDXX's Equity to Asset is ranked lower than
53% of the 279 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. IDXX: 0.09 )
IDXX' s 10-Year Equity to Asset Range
Min: 0.09   Max: 0.89
Current: 0.09

0.09
0.89
Interest Coverage 16.87
IDXX's Interest Coverage is ranked higher than
57% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 178.70 vs. IDXX: 16.87 )
IDXX' s 10-Year Interest Coverage Range
Min: 16.87   Max: 9999.99
Current: 16.87

16.87
9999.99
F-Score: 5
Z-Score: 6.77
M-Score: -2.93
WACC vs ROIC
6.89%
28.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 17.52
IDXX's Operating margin (%) is ranked higher than
93% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.96 vs. IDXX: 17.52 )
IDXX' s 10-Year Operating margin (%) Range
Min: -1.67   Max: 20.3
Current: 17.52

-1.67
20.3
Net-margin (%) 12.24
IDXX's Net-margin (%) is ranked higher than
92% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.43 vs. IDXX: 12.24 )
IDXX' s 10-Year Net-margin (%) Range
Min: -8.02   Max: 14.26
Current: 12.24

-8.02
14.26
ROE (%) 49.70
IDXX's ROE (%) is ranked higher than
99% of the 272 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. IDXX: 49.70 )
IDXX' s 10-Year ROE (%) Range
Min: -6.75   Max: 57.23
Current: 49.7

-6.75
57.23
ROA (%) 14.10
IDXX's ROA (%) is ranked higher than
97% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. IDXX: 14.10 )
IDXX' s 10-Year ROA (%) Range
Min: -5.62   Max: 17.84
Current: 14.1

-5.62
17.84
ROC (Joel Greenblatt) (%) 56.22
IDXX's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 294 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. IDXX: 56.22 )
IDXX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2.93   Max: 96.66
Current: 56.22

-2.93
96.66
Revenue Growth (3Y)(%) 11.80
IDXX's Revenue Growth (3Y)(%) is ranked higher than
88% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. IDXX: 11.80 )
IDXX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 8.4   Max: 23.1
Current: 11.8

8.4
23.1
EBITDA Growth (3Y)(%) 8.70
IDXX's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.70 vs. IDXX: 8.70 )
IDXX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 2.4   Max: 98.1
Current: 8.7

2.4
98.1
EPS Growth (3Y)(%) 8.80
IDXX's EPS Growth (3Y)(%) is ranked higher than
81% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. IDXX: 8.80 )
IDXX' s 10-Year EPS Growth (3Y)(%) Range
Min: -0.8   Max: 26.4
Current: 8.8

-0.8
26.4
» IDXX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

IDXX Guru Trades in Q2 2014

RS Investment Management 168,010 sh (New)
Paul Tudor Jones 1,600 sh (New)
Jim Simons 151,400 sh (+157.05%)
Chris Davis 185,256 sh (+3.16%)
Chuck Royce 1,203,911 sh (unchged)
Jean-Marie Eveillard Sold Out
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Ruane Cunniff 5,238,390 sh (-0.27%)
Ron Baron 3,692,912 sh (-0.99%)
Jeremy Grantham 25,600 sh (-4.12%)
Bill Frels 2,999 sh (-40.01%)
» More
Q3 2014

IDXX Guru Trades in Q3 2014

Joel Greenblatt 155,323 sh (New)
Ray Dalio 7,113 sh (New)
Paul Tudor Jones 10,541 sh (+558.81%)
Jeremy Grantham 50,406 sh (+96.90%)
Jim Simons 292,052 sh (+92.90%)
Chris Davis 323,495 sh (+74.62%)
RS Investment Management 192,520 sh (+14.59%)
Bill Frels 3,199 sh (+6.67%)
Ron Baron 3,670,909 sh (-0.60%)
Ruane Cunniff 5,197,081 sh (-0.79%)
Chuck Royce 1,147,031 sh (-4.72%)
» More
Q4 2014

IDXX Guru Trades in Q4 2014

John Hussman 36,300 sh (New)
Jim Simons 318,752 sh (+9.14%)
Chris Davis 351,787 sh (+8.75%)
RS Investment Management 201,600 sh (+4.72%)
Ruane Cunniff 4,448,407 sh (unchged)
Ruane Cunniff 4,639,121 sh (unchged)
Ruane Cunniff 4,639,121 sh (unchged)
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Ron Baron 3,623,004 sh (-1.30%)
Chuck Royce 994,811 sh (-13.27%)
Ruane Cunniff 4,448,407 sh (-14.41%)
Jeremy Grantham 41,800 sh (-17.07%)
Bill Frels 2,199 sh (-31.26%)
Paul Tudor Jones 2,200 sh (-79.13%)
» More
2015

IDXX Guru Trades in 2015

Ron Baron 3,623,004 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on IDEXX Laboratories Inc

Baron Funds Comments on IDEXX Laboratories Inc - Mar 23, 2015

Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose in the fourth quarter on better-than-expected earnings and progress on moving to a direct distribution model in the U.S. IDEXX’s fundamentals continue to improve, with organic growth in its core business reaching 12% in the most recently reported quarter. We believe organic revenue growth at current levels is sustainable due to recent innovations in IDEXX’s portfolio of diagnostic products, instruments, data management tools, and geographic expansion. (Rebecca Ellin)

From Ron Baron (Trades, Portfolio)'s Baron Partners Fund Fourth Quarter 2014 Commentary.

Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - May 02, 2014

Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose on evidence of improving organic growth and excitement around its launch of CatalystOne, a new diagnostic platform. During its most recent quarter, IDEXX's organic revenue growth improved from mid-single digits to 11%, helped by strong instrument sales and accelerating volumes for the associated consumables. We believe that recent innovations in its diagnostic products, data management capabilities, and its go-to-market strategy have positioned IDEXX to continue recent market share gains and to significantly accelerate its revenue growth.



From Baron Funds' first quarter 2014 commentary.





Check out Ron Baron latest stock trades

Top Ranked Articles about IDEXX Laboratories Inc

Baron Funds Comments on IDEXX Laboratories Inc
Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose in the fourth quarter on better-than-expected earnings and progress on moving to a direct distribution model in the U.S. IDEXX’s fundamentals continue to improve, with organic growth in its core business reaching 12% in the most recently reported quarter. We believe organic revenue growth at current levels is sustainable due to recent innovations in IDEXX’s portfolio of diagnostic products, instruments, data management tools, and geographic expansion. (Rebecca Ellin) Read more...
Ruane Cunniff Sells Portions of Five of its Top 10 Stakes
In contrast to its activity in the third quarter, when nearly half of its transactions involved buying stocks in companies that were new to its portfolio, the majority of Ruane Cunniff (Trades, Portfolio)’s fourth-quarter activity involved selling – including portions of five of its 10 largest existing stakes. Read more...
Baron Funds Comments on IDEXX Laboratories
Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose on evidence of improving organic growth and excitement around its launch of CatalystOne, a new diagnostic platform. During its most recent quarter, IDEXX's organic revenue growth improved from mid-single digits to 11%, helped by strong instrument sales and accelerating volumes for the associated consumables. We believe that recent innovations in its diagnostic products, data management capabilities, and its go-to-market strategy have positioned IDEXX to continue recent market share gains and to significantly accelerate its revenue growth. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 41.40
IDXX's P/E(ttm) is ranked higher than
77% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 41.40 )
IDXX' s 10-Year P/E(ttm) Range
Min: 15.21   Max: 46.98
Current: 41.4

15.21
46.98
Forward P/E 30.03
IDXX's Forward P/E is ranked higher than
76% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 30.03 )
N/A
PE(NRI) 42.90
IDXX's PE(NRI) is ranked higher than
83% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 42.90 )
IDXX' s 10-Year PE(NRI) Range
Min: 15.18   Max: 46.93
Current: 42.9

15.18
46.93
P/B 60.60
IDXX's P/B is ranked lower than
68% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. IDXX: 60.60 )
IDXX' s 10-Year P/B Range
Min: 3.73   Max: 67.91
Current: 60.6

3.73
67.91
P/S 5.10
IDXX's P/S is ranked higher than
50% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.66 vs. IDXX: 5.10 )
IDXX' s 10-Year P/S Range
Min: 1.75   Max: 5.7
Current: 5.1

1.75
5.7
PFCF 42.90
IDXX's PFCF is ranked higher than
77% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 42.90 )
IDXX' s 10-Year PFCF Range
Min: 12.97   Max: 240
Current: 42.9

12.97
240
POCF 33.00
IDXX's POCF is ranked higher than
79% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 33.00 )
IDXX' s 10-Year POCF Range
Min: 11.37   Max: 36.08
Current: 33

11.37
36.08
EV-to-EBIT 30.05
IDXX's EV-to-EBIT is ranked higher than
83% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 30.05 )
IDXX' s 10-Year EV-to-EBIT Range
Min: 10.7   Max: 33.3
Current: 30.05

10.7
33.3
PEG 3.70
IDXX's PEG is ranked higher than
92% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 3.70 )
IDXX' s 10-Year PEG Range
Min: 0.77   Max: 3.84
Current: 3.7

0.77
3.84
Shiller P/E 50.10
IDXX's Shiller P/E is ranked higher than
79% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 50.10 )
IDXX' s 10-Year Shiller P/E Range
Min: 20.68   Max: 61.56
Current: 50.1

20.68
61.56
Current Ratio 0.93
IDXX's Current Ratio is ranked lower than
52% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. IDXX: 0.93 )
IDXX' s 10-Year Current Ratio Range
Min: 0.93   Max: 7.84
Current: 0.93

0.93
7.84
Quick Ratio 0.73
IDXX's Quick Ratio is ranked lower than
52% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. IDXX: 0.73 )
IDXX' s 10-Year Quick Ratio Range
Min: 0.73   Max: 7
Current: 0.73

0.73
7
Days Inventory 80.26
IDXX's Days Inventory is ranked higher than
77% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 141.40 vs. IDXX: 80.26 )
IDXX' s 10-Year Days Inventory Range
Min: 77.45   Max: 165.44
Current: 80.26

77.45
165.44
Days Sales Outstanding 37.43
IDXX's Days Sales Outstanding is ranked higher than
92% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 81.46 vs. IDXX: 37.43 )
IDXX' s 10-Year Days Sales Outstanding Range
Min: 37.43   Max: 91.54
Current: 37.43

37.43
91.54

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 3.10
IDXX's Price/DCF (Projected) is ranked higher than
81% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 3.10 )
IDXX' s 10-Year Price/DCF (Projected) Range
Min: 1.74   Max: 3.11
Current: 3.1

1.74
3.11
Price/Median PS Value 1.30
IDXX's Price/Median PS Value is ranked higher than
65% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. IDXX: 1.30 )
IDXX' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 2.27
Current: 1.3

0.47
2.27
Price/Peter Lynch Fair Value 3.40
IDXX's Price/Peter Lynch Fair Value is ranked higher than
90% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IDXX: 3.40 )
IDXX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.99   Max: 3.41
Current: 3.4

0.99
3.41
Earnings Yield (Greenblatt) 3.30
IDXX's Earnings Yield (Greenblatt) is ranked higher than
75% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. IDXX: 3.30 )
IDXX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3   Max: 9.4
Current: 3.3

3
9.4
Forward Rate of Return (Yacktman) 14.14
IDXX's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. IDXX: 14.14 )
IDXX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 14   Max: 22.6
Current: 14.14

14
22.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:IX1.Germany,
IDEXX Laboratories Inc was incorporated in 1983. The Company develops, manufactures and distributes products and provides services for the veterinary, bioresearch, water, livestock, poultry and dairy markets. It also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. The Company operates through three segments: CAG, Water, and LPD. CAG develops, designs, manufactures and distributes products and performs services for veterinarians and the bioresearch market related to diagnostics and information management. Water develops, designs, manufactures and distributes a products used in the detection of various microbiological parameters in water. LPD develops, designs, manufactures and distributes diagnostic tests and related instrumentation that are used to manage the health status of livestock and poultry, to improve bovine reproductive efficiency, and to ensure the quality and safety of milk and food. OPTI Medical develops, designs, manufactures and distributes point-of-care electrolyte and blood gas analyzers and related consumable products for the human medical diagnostics market. It competes with many companies ranging from large human pharmaceutical and medical diagnostics companies to small businesses focused on animal health. Its companion animal veterinary diagnostic products and services compete with both reference laboratory service and in-clinic product providers. The Company's trademarks include 4Dx, Catalyst Dx, Catalyst One, Coag Dx, Colilert, Colisure, Cornerstone, DVMAX, Enterolert, Feline Triple, Filta-Max, Filta-Max xpress, IDEXX I-Vision CR, IDEXX I-Vision DR, IDEXX I-Vision Mobile, IDEXX ImageBank, IDEXX-PACS, IDEXX VetLab, IDEXX VPM, LaserCyte, LaserCyte Dx, Navigator, OPTI, OPTI LION, PetChek, PetDetect, Pet Health Network, Practice Profile, ProCyte Dx, Pseudalert, Quanti-Tray, SimPlate, SmartService, SNAP, SNAPduo, SNAP Pro, SNAP cPL, SNAP fPL, SNAPshot Dx, VetAutoread, VetConnect, VetLab UA, VetLINK, VetLyte, VetStat, VetTest and VetVault. Many of its products are subject to comprehensive regulation by U.S. and foreign regulatory agencies that relate to, among other things, product approvals, manufacturing, distribution, marketing and promotion, labeling, recordkeeping, testing, quality, storage and product disposal.
» More Articles for IDXX

Headlines

Articles On GuruFocus.com
Baron Funds Comments on IDEXX Laboratories Inc Mar 23 2015 
Ron Baron's Baron Partners Fund Fourth Quarter 2014 Commentary Mar 20 2015 
Baron Asset Fund Commentary on IDEX Corp Mar 19 2015 
Ruane Cunniff Sells Portions of Five of its Top 10 Stakes Mar 13 2015 
Baron Funds Comments on IDEXX Laboratories May 02 2014 
IDEXX Laboratories, Inc. - Value Alert May 23 2013 
Weekly Top Insider Sells Feb 11 2013 
Weekly CFO Sells Highlight: FB, FSL, IVZ, IDXX, PFMT, CTXS Feb 11 2013 
Baron Funds Comments on IDEXX Laboratories Feb 06 2013 
Baron Funds Comments on IDEXX Laboratories Aug 23 2012 

More From Our Partners
IDEXX Banks on Strong CAG, Global Growth Continues - Analyst Blog Apr 1 2015 - ZACKS

More From Other Websites
IDEXX Names Jeffrey Fiarman Executive Vice President and General Counsel Apr 15 2015
IDEXX M. bovis Ab Test Earns USDA Approval Apr 15 2015
IDEXX Laboratories to Release 2015 First Quarter Financial Results Apr 08 2015
IDEXX Banks on Strong CAG, Global Growth Continues - Analyst Blog Apr 01 2015
IDEXX I-Vision DR ® System Added to Digital Imaging Offerings Mar 21 2015
IDEXX Announces Federal Trade Commission Final Approval of Consent Agreement Mar 07 2015
IDEXX Laboratories to Present at Raymond James Institutional Investors Conference Feb 24 2015
IDEXX LABORATORIES INC /DE Financials Feb 21 2015
10-K for IDEXX Laboratories, Inc. Feb 19 2015
IDEXX LABORATORIES INC /DE Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Feb 19 2015
IDEXX LABORATORIES INC /DE Files SEC form 10-K, Annual Report Feb 17 2015
IDEXX Tops Q4 Earnings, Lags Revenues; Tweaks 2015 View - Analyst Blog Feb 02 2015
Idexx tops 4Q profit forecasts Jan 30 2015
Idexx tops 4Q profit forecasts Jan 30 2015
Q4 2014 IDEXX Laboratories Inc Earnings Release - Before Market Open Jan 30 2015
IDEXX LABORATORIES INC /DE Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 30 2015
IDEXX Laboratories Announces Fourth Quarter Results Jan 30 2015
Top Large-Cap Growth Stock Funds: Back On Their Feet Jan 28 2015
Meridian Bioscience: In-line Earnings, Revenue Beat in Q1 - Analyst Blog Jan 26 2015
IDEXX Laboratories to Release 2014 Fourth Quarter and Full-Year Financial Results Jan 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK